Literature DB >> 34659806

Development and validation of a nomogram model for early postoperative hyperlactatemia in patients undergoing cardiac surgery.

Su Wang1, Dashuai Wang2, Xiaofan Huang2, Hongfei Wang2, Sheng Le2, Jinnong Zhang1, Xinling Du2.   

Abstract

BACKGROUND: Postoperative hyperlactatemia (POHL) is common in patients undergoing cardiac surgery, associated with adverse outcomes. The aim of this study was to identify predictors for POHL after cardiac surgery and to develop and validate a predictive model.
METHODS: Adult patients who underwent open heart surgery at our institution between 2016 and 2019 were retrospectively included. The patients were randomly divided into training and validation groups at a 2:1 ratio. Multivariate logistic regression was performed to identify independent predictors for POHL in the training set. A nomogram was then constructed and was validated in the validation set.
RESULTS: POHL developed in 713 of the 5,323 patients (13.4%). The mortality rate was higher in patients with POHL compared with patients without that (9.5% vs. 2.1%, P<0.001). Age, white blood cell (WBC) count, left ventricular ejection fraction, renal insufficiency, cardiac surgery history, red blood cell (RBC) transfusion, and cardiopulmonary bypass (CPB) time were identified as independent risk factors. The nomogram based on these predictors indicated good discrimination in both the training (c-index: 0.787) and validation (c-index: 0.820) sets. The calibration was reasonable by both visual inspection and goodness-of-fit test. The decision and clinical impact curves demonstrated good clinical utility.
CONCLUSIONS: We identified 7 independent risk factors and derived a prediction model for POHL in patients undergoing cardiac surgery. The model may contribute significantly to early risk assessment and clinical intervention. 2021 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Postoperative hyperlactatemia (POHL); cardiac surgery; nomogram; prediction model; risk factor

Year:  2021        PMID: 34659806      PMCID: PMC8482329          DOI: 10.21037/jtd-21-1004

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


Introduction

Hyperlactatemia is a common complication in critically ill patients and is a strong indicator for poor prognosis (1). The development of hyperlactatemia in intensive care unit (ICU) is closely associated with increased mortality among different critically ill patients including those undergoing cardiac surgery (2). The association between postoperative hyperlactatemia (POHL) and various adverse outcomes has been widely reported, such as cardiogenic shock, acute renal failure, acute respiratory distress syndrome, and mortality (3-6). The incidence of POHL differed considerably in the literature, with reported rates of 20.6–71.8% (4,5,7). The bimodal distribution of POHL has been seen in patients undergoing cardiac surgery. Early-onset hyperlactatemia occurs during or soon after cardiopulmonary bypass (CPB) and late-onset hyperlactatemia develops within the first 12 hours after ICU admission (8). Some studies focused on identifying independent risk factors for POHL after cardiac surgery have been conducted and several predictors have been reported, such as elevated level of preoperative serum creatinine, longer CPB duration, higher blood glucose and reduced oxygen delivery (9,10). However, the physiological and clinical data suggested that late-onset hyperlactatemia was not attributed to impaired tissue perfusion or oxygen delivery, and the influencing factors may vary with time (11). Furthermore, although several risk factors have been described in the literature (4,12,13), to our knowledge, there are no existing nomogram models to predict the occurrence of POHL in patients undergoing cardiac surgery. The construction of a specific and sensitive nomogram model for POHL after cardiac surgery is still urgently needed. The aims of this study were to identify preoperative and intraoperative predictors for POHL in patients undergoing cardiac surgery, and to establish and validate a nomogram model to help with risk evaluation and clinical prevention. We present the following article in accordance with the TRIPOD reporting checklist (available at https://dx.doi.org/10.21037/jtd-21-1004).

Methods

Ethical statement

This study was approved by the Medical Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (IORG No. IORG0003571) and was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Written informed consent was waived due to the retrospective, observational nature.

Patient selection

We included consecutive adult patients undergoing open heart surgery from January 2016 to December 2019 in a tertiary care center with more than 6,000 beds, located in Wuhan, China. All patients undergoing cardiac surgery were admitted to the ICU postoperatively and received mechanical ventilatory support. The exclusion criteria were set as follows: intraoperative death, immunosuppression or immune deficiency, organ transplantation, and incomplete data recording.

Data collection

We obtained clinical data through electronic medical record system of our institution. Demographics included age, gender, calculated body mass index, history of smoking and drinking. Comorbidities contained hypertension, diabetes mellitus, cerebrovascular disease, pericardial effusion, left ventricular ejection fraction (LVEF), atrial fibrillation, pulmonary artery hypertension, chronic obstructive pulmonary disease, gastrointestinal tract disease, renal insufficiency, peripheral vascular disease, cardiac and general surgical history. Laboratory variables included red blood cell (RBC) count, hemoglobin, white blood cell (WBC) count, platelet count, serum creatinine, globulin, albumin, total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transpeptidase. Operative variables included surgical types, blood transfusion, CPB and aortic cross clamp time. Postoperative data included postoperative pneumonia, readmission to ICU, reintubation, tracheotomy, intra-aortic balloon pump, continuous renal replacement therapy, mortality, and the lengths of mechanical ventilation, ICU and hospital stay.

Measurement and definition

The concentration of arterial lactate was measured using a blood gas analyzer (Radiometer, type ABL80PLEX, Denmark). The recorded value represented the peak blood lactate value in the first 12 hours postoperatively. In this study, POHL was defined as arterial blood lactate level exceeding 4 mmol/L with reference to previous studies (7,14). Body mass index was calculated as weight (kg)/height (m2). Smoking history was defined as current or previous daily smoking. Drinking history was defined as having a history of habitual drinking. Hypertension was defined as blood pressure ≥140/90 mmHg, medication for hypertension, or a history of hypertension. Diabetes mellitus was defined as fasting glucose ≥7.0 mmol/L, non-fasting glucose ≥11.1 mmol/L, medication for diabetes, or self-reported diabetes mellitus. Chronic obstructive pulmonary disease was defined as FEV1/FVC ≤0.7. Renal insufficiency was defined as serum creatinine >110 μmol/L or previous diagnosis of renal insufficiency.

Statistical analysis

Statistical analyses were performed using R software (version 4.0.3). A two-tailed P value <0.05 was considered statistically significant. Categorical variables were expressed as frequency (percentage) and analyzed by the chi-square test or Fisher’s exact test. Normally distributed continuous variables were presented as means ± standard deviations and analyzed by Student’s t-test. Non-normally distributed variables were expressed as medians with inter-quartile ranges and analyzed by Mann-Whitney U test. The complete datasets were randomly divided into training and validation sets by 2:1 ratio. The former was applied for model establishment, and the latter was applied for model validation. In the training set, the preoperative and intraoperative variables were first analyzed by univariate analysis to screen possible risk factors for POHL. Variables with P value <0.1 were then included in multivariate logistic regression analysis to identify independent risk factors. Based on the multivariate model, a nomogram was constructed to facilitate a better prediction of POHL after cardiac surgery. Internal validation of the nomogram model was evaluated by bootstrapping using 1,000 replications. External validation was conducted in the independent validation set. One smoothed non-parametric calibration curve and one fitted logistic calibration curve were used to visually assess the calibration. The Hosmer-Lemeshow goodness-of-fit statistic was also calculated. The area under the receiver operating characteristic (ROC) curve (AUC) or c-index was employed to evaluate the discrimination. Comparison of the AUC between two sets was performed using the Delong method (15). Decision curve analysis was utilized to evaluate the clinical utility of the model. The decision curve exhibited standardized net benefit against threshold probability. The clinical impact curve displayed the number of judged high risk with different threshold probability and the number of true positives among 1,000 patients.

Results

Baseline demographics and clinical characteristics

Among the 5,784 adult patients who underwent cardiac surgery, 5 died intraoperatively, 375 had immunosuppression, immune deficiency or organ transplantation, and 81 had missing data (). The remaining 5,323 cases fulfilled the inclusion criteria and were further analyzed (). The average age of the included patients was 51.2 years, and 56.4% were males. The overall incidence of POHL was 13.4%.
Figure 1

Flow chart of the study. POHL, postoperative hyperlactatemia.

Table 1

Comparison of characteristics between the training and validation sets

CharacteristicTraining set, n=3,549 (%)Validation set, n=1,774 (%)P value
Demographics
   Male1,982 (55.8)1,019 (57.4)0.269
   Age (years)51.34±12.8150.85±13.120.196
   Body mass index (kg/m2)23.1 (20.9, 25.5)23.2 (20.9, 25.6)0.806
   Smoking history1,029 (29.0)519 (29.3)0.843
   Drinking history769 (21.7)385 (21.7)0.977
Underlying conditions
   Hypertension1,073 (30.2)531 (29.9)0.821
   Diabetes mellitus289 (8.1)149 (8.4)0.749
   Chronic obstructive pulmonary disease377 (10.6)180 (10.1)0.593
   Cerebrovascular disease1,213 (34.2)599 (33.8)0.764
   Renal insufficiency336 (9.5)188 (10.6)0.192
   Gastrointestinal tract disease300 (8.5)147 (8.3)0.836
   Atrial fibrillation600 (16.9)312 (17.6)0.534
   General surgery history997 (28.1)500 (28.2)0.944
   Cardiac surgery history241 (6.8)135 (7.6)0.271
   Pulmonary artery hypertension915 (25.8)475 (26.8)0.437
   Pericardial effusion504 (14.2)252 (14.2)0.997
   Left ventricular ejection fraction (%)62 [58, 66]62 [58, 67]0.270
Laboratory values
   White blood cell count (×109/L)5.8 (4.8, 7.1)5.9 (4.8, 7.2)0.108
   Red blood cell count (×1012/L)4.3 (3.9, 4.6)4.3 (3.9, 4.6)0.329
   Hemoglobin (g/L)129 (118, 140)130 (118, 141)0.119
   Platelet count (×109/L)180 (144, 221)179 (145, 221)0.738
   Serum creatinine (μmol/L)71.9 (60.9, 85.3)72.1 (60.9, 85.3)0.613
   Serum albumin (g/L)40.4 (37.9, 42.6)40.4 (38.0, 42.8)0.341
   Serum globulin (g/L)24.3 (21.6, 27.3)24.5 (21.8, 27.3)0.253
   Total bilirubin (μmol/L)13.5 (10.3, 18.6)13.3 (10.3, 18.3)0.585
   Direct bilirubin (μmol/L)4.1 (3.4, 6.2)4.3 (3.5, 6.3)0.128
   Alanine aminotransferase (U/L)20.4 (17.3, 30.7)20.5 (17.5, 40.0)0.509
   Aspartate aminotransferase (U/L)25.0 (20.7, 36.2)24.8 (20.6, 36.0)0.555
   Gamma-glutamyl transpeptidase (U/L)20.8 (17.2, 30.2)21.1 (17.1, 31.1)0.347
Operative variables
   Isolated valve surgery1,920 (54.1)977 (55.1)0.501
   Isolated coronary artery bypass grafting415 (11.7)176 (9.9)0.058
   Mixed valve and coronary surgery310 (8.7)171 (9.6)0.278
   Aortic surgery604 (17.0)300 (16.9)0.921
   Other types300 (8.5)150 (8.5)0.998
   Emergent cardiac surgery335 (9.4)157 (8.9)0.484
   Cardiopulmonary bypass time (minutes)105 [78, 142]106 [79, 142]0.556
   Aortic cross clamp time (minutes)69 [46, 96]69 [47, 94]0.897
   Transfusion of red blood cells (units)1 [1, 3]1 [1, 3]0.639
Flow chart of the study. POHL, postoperative hyperlactatemia. Of the 5,323 operations, isolated valve replacement or repair was performed for 2,897 cases (54.4%), isolated coronary artery bypass grafting for 591 cases (11.1%), mixed valve surgery and coronary artery bypass grafting for 481 cases (9.0%), aortic surgery for 904 cases (17.0%), and other types for 450 cases (8.5%). The study population had different comorbidities. Patients with smoking history made up 29.1%, drinking history 21.7%, diabetes mellitus 8.2%, hypertension 30.1%, atrial fibrillation 17.1%, chronic obstructive pulmonary disease 10.5%, gastrointestinal tract disease 8.4%, renal insufficiency 9.8%, cardiac surgery history 7.1%. The average duration of CPB was 105 minutes, and the median volume of intraoperative transfusion of RBC was 1 unit. The baseline characteristics, comorbidities and operative variables were similar in the training and validation sets (). The incidence of POHL in the two sets was 13.1% and 14.0%, respectively (P=0.38).

Development of the nomogram model

Univariate analysis of possible predictors for POHL after cardiac surgery in the training set was displayed in . Before the construction of a multivariate model, collinearity diagnostics were performed. Significant risk factors in the univariate analysis were further entered into the multivariate logistic regression analysis. Seven independent predictors associated with the development of POHL were identified, including renal insufficiency, cardiac surgery history, WBC count, age, LVEF, intraoperative transfusion of RBC, and CPB time (). A nomogram used to predict the risk of POHL after cardiac surgery was established based on the multivariate logistic regression model (). Regression coefficients of the variables were scaled to scores within the range of 0–100, reflecting their relative importance.
Table 2

Univariate analysis of possible risk factors for POHL after cardiac surgery in the training set

CharacteristicWithout POHL, n=3,084 (%)With POHL, n=465 (%)χ2/Z/tP value
Demographics
   Male1,695 (55.0)287 (61.7)7.4870.006
   Age (years)51.09±12.9952.94±11.443.1890.001
   Body mass index (kg/m2)23.0 (20.8, 25.4)23.8 (21.5, 26.0)4.262<0.001
   Smoking history867 (28.1)162 (34.8)8.8790.003
   Drinking history655 (21.2)114 (24.5)2.5570.110
Underlying conditions
   Hypertension874 (28.3)199 (42.8)40.032<0.001
   Diabetes mellitus264 (8.6)25 (5.4)5.4760.019
   Chronic obstructive pulmonary disease316 (10.2)61 (13.1)3.5100.061
   Cerebrovascular disease1,047 (33.9)166 (35.7)0.5500.458
   Renal insufficiency234 (7.6)102 (21.9)97.051<0.001
   Gastrointestinal tract disease260 (8.4)40 (8.6)0.0150.901
   Atrial fibrillation509 (16.5)91 (19.6)2.7030.100
   General surgery history884 (28.7)113 (24.3)3.8080.051
   Heart surgery history183 (5.9)58 (12.5)27.299<0.001
   Pulmonary artery hypertension809 (26.2)106 (22.8)2.4940.114
   Pericardial effusion426 (13.8)78 (16.8)2.9080.088
   Left ventricular ejection fraction (%)62 [59, 66]60 [56, 65]3.875<0.001
Laboratory values
   White blood cell count (×109/L)5.7 (4.7, 7.0)6.2 (5.1, 8.8)6.760<0.001
   Red blood cell count (×1012/L)4.3 (3.9, 4.6)4.3 (3.9, 4.6)0.2200.826
   Hemoglobin (g/L)129 (118, 140)130 (119, 140)0.5630.573
   Platelet count (×109/L)182 (144, 224)173 (137, 205)3.721<0.001
   Serum creatinine (μmol/L)71.2 (60.6, 84.5)76.2 (62.8, 94.3)4.992<0.001
   Serum albumin (g/L)40.5 (38.0, 42.7)40.0 (37.1, 42.1)3.4200.001
   Serum globulin (g/L)24.2 (21.6, 27.2)24.9 (21.9, 27.6)2.2450.025
   Total bilirubin (μmol/L)13.4 (10.2, 18.4)14.0 (10.7, 19.8)3.0500.002
   Direct bilirubin (μmol/L)4.1 (3.4, 6.2)4.1 (3.5, 6.7)2.5720.010
   Alanine aminotransferase (U/L)20.2 (17.3, 30.7)20.9 (17.5, 31.2)1.3830.167
   Aspartate aminotransferase (U/L)24.9 (20.7, 35.7)26.9 (21.4, 38.6)2.8850.004
   Gamma-glutamyl transpeptidase (U/L)20.7 (17.2, 29.9)21.9 (17.4, 31.7)2.0920.036
Operative variables
   Surgical types192.822<0.001
    Isolated valve surgery1,740 (56.4)180 (38.7)
    Isolated coronary artery bypass grafting381 (12.4)34 (7.3)
    Mixed valve and coronary surgery236 (7.7)74 (15.9)
    Aortic surgery439 (14.2)165 (35.5)
    Other types288 (9.3)12 (2.6)
   Emergent cardiac surgery208 (6.7)127 (27.3)199.958<0.001
   Cardiopulmonary bypass time (minutes)100 [75, 132]157 [114, 220]18.328<0.001
   Aortic cross clamp time (minutes)66 [44, 89]99 [69, 130]15.323<0.001
   Transfusion of red blood cells (units)1 [1, 3]1 [3, 6]15.204<0.001

POHL, postoperative hyperlactatemia.

Table 3

Multivariate analysis of independent risk factors for POHL after cardiac surgery

CharacteristicCoefficientStandard errorOR (95% CI)P value
Renal insufficiency0.3540.1561.425 (1.049–1.935)0.024
Cardiac surgery history0.6780.1811.970 (1.383–2.806)<0.001
WBC count (×109/L)0.0460.0191.047 (1.008–1.088)0.017
Age (years)0.0100.0051.010 (1.001–1.019)0.038
LVEF (%)−0.0280.0070.973 (0.960–0.986)<0.001
Transfusion of RBC (units)0.1610.0241.175 (1.120–1.233)<0.001
CPB time (minutes)0.7670.0722.152 (1.867–2.481)<0.001
Intercept−3.6070.5340.027<0.001

CI, confidence interval; CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction; OR, odds ratio; POHL, postoperative hyperlactatemia; RBC, red blood cell; WBC, white blood cell.

Figure 2

Development, assessment and validation of the nomogram model. (A) Nomogram predicting the development of postoperative hyperlactatemia in patients undergoing cardiac surgery; (B) ROC curves for the nomogram in the training and validation sets; (C) calibration plot of the nomogram in the training set; and (D) calibration plot of the nomogram in the validation set. AUC, area under the receiver operating characteristic curve; CI, confidence interval; CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction; RBC, red blood cell; ROC, receiver operating characteristic; WBC, white blood cell.

POHL, postoperative hyperlactatemia. CI, confidence interval; CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction; OR, odds ratio; POHL, postoperative hyperlactatemia; RBC, red blood cell; WBC, white blood cell. Development, assessment and validation of the nomogram model. (A) Nomogram predicting the development of postoperative hyperlactatemia in patients undergoing cardiac surgery; (B) ROC curves for the nomogram in the training and validation sets; (C) calibration plot of the nomogram in the training set; and (D) calibration plot of the nomogram in the validation set. AUC, area under the receiver operating characteristic curve; CI, confidence interval; CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction; RBC, red blood cell; ROC, receiver operating characteristic; WBC, white blood cell. The probability of POHL after cardiac surgery in a specific patient can be calculated easily by summing the scores of all associated factors. Older patients who had renal insufficiency, previous cardiac surgery, higher WBC count, lower LVEF, more intraoperative transfusion of RBC, and longer duration of CPB had higher scores and thus higher risk of POHL after cardiac surgery.

Assessment and validation of the nomogram model

Both internal and external validation were used to validate the nomogram model. One thousand bootstrap resamples were used for internal validation in the training set. External validation was performed in the independent validation set. To evaluate the predictive capability of the nomogram, the ROC curves were drawn (). The AUCs in the training and validation sets were respectively 0.79 (95% CI, 0.77–0.81) and 0.82 (95% CI, 0.79–0.85), both indicating reasonable discrimination. To assess the calibration of the nomogram model, Hosmer-Lemeshow goodness-of-fit test was used, and calibration curves were plotted. The model was well calibrated in both the training (Hosmer-Lemeshow χ2=11.88, P=0.16) and validation sets (Hosmer-Lemeshow χ2=9.94, P=0.27). By visual inspection, the nomogram also showed good calibration in the two sets ().

Clinical utility of the nomogram model

To evaluate the clinical utility of the prediction model, decision curve analysis was performed, as well as graphical decision and clinical impact curves. The decision curves of the model demonstrated that compared with “intervention for all” or “no intervention” strategies, more clinical net benefits could be obtained using the nomogram model when the risk threshold was between 0.02 and 0.60 (). The clinical impact curves also illustrated that the nomogram model had remarkable predictive power and exhibited good clinical utility ().
Figure 3

Decision curve analysis of the nomogram model. Decision curves of the nomogram in the training (A) and validation sets (B), and clinical impact curves of the nomogram in the training (C) and validation sets (D).

Decision curve analysis of the nomogram model. Decision curves of the nomogram in the training (A) and validation sets (B), and clinical impact curves of the nomogram in the training (C) and validation sets (D).

Risk stratification

According to the nomogram model, we defined four risk groups as very low risk (<94 points), low risk (94–118 points), medium risk (119–162 points), and high risk (>162 points) for POHL after cardiac surgery (). The corresponding cutoff values of the estimated probabilities was 0.05, 0.1, and 0.3. In this study, about 30% of the patients were respectively divided into very low-, low-, and medium-risk groups, and about 10% into high-risk group. The difference of probabilities between each risk interval was significant (P<0.05) and the model-based risk stratification performed well.
Table 4

Risk intervals of POHL based on the nomogram model

Risk intervalsVery low-risk (<94 points)Low-risk (94–118 points)Medium-risk (119–162 points)High-risk (>162 points)
Estimated probability (%)<55–1010–30>30
Observed probability, % (95% CI)1.9 (1.2–2.7)7.6 (6.3–8.9)17.2 (15.3–19.0)47.4 (43.4–51.4)
No. of patients (%)1,438 (27.0)1,709 (32.1)1,577 (29.6)599 (11.3)

CI, confidence interval; POHL, postoperative hyperlactatemia.

CI, confidence interval; POHL, postoperative hyperlactatemia.

Outcomes

POHL developed in 713 of the 5,323 patients (13.4%). The overall mortality rate was 3.1%, with a rate of 9.5% in patients with POHL versus 2.1% in those without POHL (P<0.001). Furthermore, POHL was associated with a significantly higher rate of intra-aortic balloon pump requirement, continuous renal replacement therapy requirement, postoperative pneumonia, readmission to ICU, reintubation, and tracheotomy. The postoperative lengths of mechanical ventilation, ICU and hospital stay also extended significantly in patients with POHL. Details of comparison between patients with and without POHL after cardiac surgery were presented in .
Table 5

Postoperative variables in patients with and without POHL after cardiac surgery

VariablesAll patients, n=5,323 (%)Without POHL, n=4,610 (%)With POHL, n=713 (%)χ2/ZP value
Postoperative pneumonia530 (10.0)341 (7.4)189 (26.5)251.547<0.001
Reintubation247 (4.6)171 (3.7)76 (10.7)67.403<0.001
Tracheotomy128 (2.4)75 (1.6)53 (7.4)88.711<0.001
Intra-aortic balloon pump153 (2.9)83 (1.8)70 (9.8)142.172<0.001
Continuous renal replacement therapy162 (3.0)100 (2.2)62 (8.7)89.136<0.001
Mechanical ventilation (hours)23 [18, 44]22 [18, 40]45 [25, 91]21.834<0.001
Readmission to ICU207 (3.9)151 (3.3)56 (7.9)34.635<0.001
ICU stay (days)3 [2, 5]3 [2, 4]5 [4, 9]22.621<0.001
Hospital stay (days)15 [11, 19]14 [11, 18]19 [14, 25]16.319<0.001
Mortality167 (3.1)99 (2.1)68 (9.5)110.960<0.001

POHL, postoperative hyperlactatemia; ICU, intensive care unit.

POHL, postoperative hyperlactatemia; ICU, intensive care unit.

Discussion

The level of blood lactate is known to be closely related to the prognosis of critically ill patients and hyperlactatemia is strongly associated with higher mortality (16), which is reconfirmed by our results. The incidence of POHL was 13.4% in this study, similar to previous reports (14,17). The overall mortality was 3.1%, but it increased significantly in patients with POHL. In addition, more frequent complications and longer hospital stays were observed in these patients, consistent with results in the literature (5,7,17). The poorer outcomes of patients with POHL emphasized the need of identifying risk factors and high-risk population. Although some studies focused on POHL have been conducted, to our knowledge, this is the first large-sized study aiming to develop and validate a nomogram model for POHL after cardiac surgery. In this study, we used clinical data of 5,323 patients to develop and validate a risk prediction model for POHL after cardiac surgery. Five preoperative and two intraoperative independent predictors were identified. The nomogram indicated good predictive power and was well calibrated. Decision curve analysis of the nomogram demonstrated good clinical utility. Four risk intervals were identified as very low-, low-, medium- and high-risk to facilitate clinical practice. The duration of CPB was identified as a significant predictor for POHL after cardiac surgery in our analysis, which was in agreement with previous studies (4,18). The association between CPB duration and early-onset or late-onset hyperlactatemia has been verified by some published studies, however, some other studies yielded different results (19-21). The occurrence of POHL after cardiac surgery may be caused by a mixture of early- and late-onset hyperlactatemia mechanisms and the change of the lactate levels was related to the physiopathologic mechanisms and the efficacy of the treatment (22). Lactate-guided therapy on patients with POHL at ICU arrival can significantly decrease the hospital mortality, and intervention at an early stage (before or during surgery) may be more valuable to reduce risk (23). The specific relationship between CPB and POHL may be complex. Tissue micro-dialysis studies indicated that CPB itself can cause elevated lactate level and increased lactate-pyruvate ratio in the myocardial and non-myocardial tissue (24,25). One prospective study observed that pulmonary lactate release following CPB could continue up to six hours, which meant that the washout of lactate from previous hypoperfused tissues could partly account for the development of POHL (26). In addition, the process of CPB exposes patients to the complex non-physiological conditions. The contact of blood components with artificial surfaces of CPB circuit could trigger inflammatory response, resulting in lactate accumulation (27,28). Miniaturized CPB circuit has been reported to be able to diminish the inflammatory response as a consequence of less exposure, and its application may be conducive to reducing the risk of POHL (29). Moreover, CPB may damage peripheral perfusion and metabolic balance due to capillary collapse and stasis, and the degree of this damage may significantly increase over time (30). Longer duration of CPB is generally accompanied by longer duration of surgery, anesthesia, and aortic cross-clamping. As a modifiable factor, minimizing the CPB duration when allowed may yield a better prognosis. Intraoperative transfusion of RBC was another independent risk factor in our analysis. Although the intended therapeutic effect of blood transfusion in cardiac surgery was to improve organ function and save life, increasing evidence indicated that transfused RBCs might actually affect tissue oxygenation and contribute to organ injury (31,32). Several studies have found that the risk of adverse outcomes may gradually increase with each more unit of RBCs transfused (33,34), which was consistent with our results. RBC transfusion could cause proinflammatory and immunosuppressive effects, and stored RBCs might be less deformable and supple, causing micro-circulatory occlusion and thus organ ischemia (35,36). Furthermore, studies revealed that decreased RBC deformability was closely associated with elevated RBC distribution width, which had a positive correlation with POHL and could even predict multiple organ dysfunction syndrome (37,38). Retrograde autologous priming has recently been reported to be an effective adjunct to reduce transfusion requirements and limit haemodilution (39). A meta-analysis also demonstrated that restrictive transfusion was safe, and a threshold of hemoglobin concentration <7.5 g/dL was recommended for patients undergoing cardiac surgery (40,41). WBC count was found to be independently associated with the development of POHL after cardiac surgery in our analysis, however, none of the published studies reported this. It is known that leukocytosis represents a proinflammatory state. Pre-existing activation of the leukocytes could impair the perfusion at microcirculatory level after CPB onset (42). Increased preoperative WBC was also found to be significantly associated with increased need for intra-aortic balloon pump, which may indirectly associate with insufficient perfusion (43). The role of leukodepletion in cardiac surgery remains unclear, however, delaying surgery to reduce the elevated WBC to normal levels when possible may help prevent POHL (44-46). Lower LVEF, renal insufficiency, previous cardiac surgery, and advanced age were also identified as independent risk factors for POHL after cardiac surgery in this study, which was also reported in previous studies (5,13,47). Lazzeri et al. found a significant relationship between LVEF and lactate values and reported that hemodynamic impairment was possibly responsible for hyperlactatemia (48). Mustafa et al. indicated that the CPB procedure decreased lactate clearance, which may be related to liver dysfunction (49). Although metabolic clearance is mainly hepatic, studies have found that the kidney also plays an important role in the clearance of lactate (50). A significant reduced lactate clearance was possibly observed in patients with renal insufficiency and hypoperfusion, leading to the development of hyperlactatemia. Zymliński et al. found that patients without clinical signs of peripheral hypoperfusion might also have an elevated lactate level, which was also related to worse prognosis (51). Some variables such as hyperglycemia and epinephrine were identified as predictors for POHL in published studies, but were not in our analysis. The role of hyperglycemia in predicting hyperlactatemia has been highlighted by Ranucci et al., and they deemed that the stress response of cardiac surgery caused this result (9). Epinephrine is always used to treat postoperative low cardiac output syndrome, whereas it may increase the incidence of POHL (4). The increased glycogenolysis may be responsible for the elevated lactate levels in patients with epinephrine administration (20). However, the postoperative cardiac output and epinephrine use were not included in our analysis due to their nature of postoperative variables and cannot be obtained early. This prediction model may play an important role in identifying high-risk POHL populations and have clinical utility in reducing the occurrence of POHL. Compared to conventional therapies, risk factors-oriented and nomogram-based early interventions may significantly improve outcomes. Some limitations should be mentioned. First, this study was conducted in a single cardiac center, which may restrict the wide application of the model to other centers. External validation in other centers may be required to further verify its clinical effectiveness. Second, it is undeniable that intraoperative and postoperative hemodynamic status and medication use may affect lactate metabolism, however, these variables were not included in our analysis. This is partly because that a large proportion of these variables are missing or have no exact records, which is mainly limited by the retrospective nature of the data collection. More appropriate design to prospectively clarify the relationship between these variables and POHL may be an interesting direction for future study. Even so, the nomogram developed using existing data also performed well in all aspects. Third, compared with some previous studies, the mortality rate is a little higher in our results. This may be partly explained by the fact that a considerable portion of included patients underwent emergent cardiac surgery and aortic dissection surgery, which may significantly increase the overall mortality. The inclusion of multiple surgical types may help obtain a larger sample size, however, studies designed specific for each type of cardiac surgery may be more instructive for clinical practice.

Conclusions

To our knowledge, this is the first large-sized study reporting nomogram for POHL after cardiac surgery. Five preoperative and two intraoperative predictors were identified by multivariate logistic regression analysis and then a nomogram was constructed and validated. The nomogram performed well in discrimination, calibration and assessment of clinical usefulness. Four risk intervals were divided to better facilitate clinical practice. The nomogram may have clinical utility in risk evaluation, identification of high-risk population, and risk modification. The article’s supplementary files as
  51 in total

1.  Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction.

Authors:  J Levraut; J P Ciebiera; S Chave; O Rabary; P Jambou; M Carles; D Grimaud
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

2.  The Incidence, Risk Factors, and Outcomes of Hyperlactatemia after Heart Transplantation.

Authors:  Yasuhiro Hoshino; Osamu Kinoshita; Minoru Ono
Journal:  Int Heart J       Date:  2017-12-27       Impact factor: 1.862

3.  Serum lactate level as a useful predictor of clinical outcome after surgery: an unfulfilled potential?

Authors:  Lorenzo Cobianchi; Andrea Peloso; Claudia Filisetti; Francesco Mojoli; Fabio Sciutti
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

4.  Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial.

Authors:  Tim C Jansen; Jasper van Bommel; F Jeanette Schoonderbeek; Steven J Sleeswijk Visser; Johan M van der Klooster; Alex P Lima; Sten P Willemsen; Jan Bakker
Journal:  Am J Respir Crit Care Med       Date:  2010-05-12       Impact factor: 21.405

5.  Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting.

Authors:  Colleen Gorman Koch; Liang Li; Andra I Duncan; Tomislav Mihaljevic; Delos M Cosgrove; Floyd D Loop; Norman J Starr; Eugene H Blackstone
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

6.  Clinical benefits of continuous leukocyte filtration during cardiopulmonary bypass in patients undergoing valvular repair or replacement.

Authors:  S W Sutton; A N Patel; V A Chase; L A Schmidt; E K Hunley; L W Yancey; R F Hebeler; E H Cheung; A C Henry; T P Meyers; R E Wood
Journal:  Perfusion       Date:  2005-01       Impact factor: 1.972

7.  High lactate levels are predictors of major complications after cardiac surgery.

Authors:  Ludhmila A Hajjar; Juliano P Almeida; Julia T Fukushima; Andrew Rhodes; Jean-Louis Vincent; Eduardo A Osawa; Filomena R B G Galas
Journal:  J Thorac Cardiovasc Surg       Date:  2013-03-15       Impact factor: 5.209

8.  Peripheral tissue metabolism during off-pump versus on-pump coronary artery bypass graft surgery: the microdialysis study.

Authors:  Marek Pojar; Jirí Mand'ák; Norbert Cibícek; Vladimír Lonský; Jan Dominik; Vladimír Palicka; Jaroslav Kubícek
Journal:  Eur J Cardiothorac Surg       Date:  2008-03-06       Impact factor: 4.191

9.  Cardiopulmonary bypass flow rate: a risk factor for hyperlactatemia after surgical repair of secundum atrial septal defect in children.

Authors:  Boban P Abraham; Parthak Prodhan; Robert D B Jaquiss; Adnan T Bhutta; Jeffrey M Gossett; Michiaki Imamura; Charles E Johnson; Michael L Schmitz; William R Morrow; Umesh Dyamenahalli
Journal:  J Thorac Cardiovasc Surg       Date:  2010-01       Impact factor: 5.209

10.  Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.

Authors:  Markus M Mueller; Hans Van Remoortel; Patrick Meybohm; Kari Aranko; Cécile Aubron; Reinhard Burger; Jeffrey L Carson; Klaus Cichutek; Emmy De Buck; Dana Devine; Dean Fergusson; Gilles Folléa; Craig French; Kathrine P Frey; Richard Gammon; Jerrold H Levy; Michael F Murphy; Yves Ozier; Katerina Pavenski; Cynthia So-Osman; Pierre Tiberghien; Jimmy Volmink; Jonathan H Waters; Erica M Wood; Erhard Seifried
Journal:  JAMA       Date:  2019-03-12       Impact factor: 56.272

View more
  1 in total

1.  Nomogram and risk calculator for severe hypoxemia after heart valve surgery.

Authors:  Xiangchao Ding; Dan Cheng; Bing Sun; Manda Sun; Chuangyan Wu; Jiuling Chen; Xiaoli Li; Yuan Lei; Yunshu Su
Journal:  Front Cardiovasc Med       Date:  2022-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.